Abstract
INTRODUCTION
Over 78 000 patients undergo non-cardiac thoracic surgery every year in the USA alone, and this number is increasing given the ageing population [1] . One in 5 patients undergoing thoracic surgery will develop postoperative atrial fibrillation or atrial flutter (POAF) [2, 3] . POAF is associated with increased morbidity and mortality after surgery. A retrospective cohort study of 20 022 patients undergoing carotid endarterectomy showed that patients who developed POAF had significantly higher risk of death (adjusted odds ratio 2.94; P = 0.002) [4] . Further, patients with POAF have an increased incidence of ischaemic stroke. In POISE, an international randomized controlled trial (RCT) of over 8000 patients undergoing non-cardiac surgery and receiving metoprolol or placebo, new clinically significant POAF was an independent predictor of stroke within 30 days after surgery [odds ratio 3.52; 95% confidence interval (CI) 1.45-8.52] [5] . Another study demonstrated that following thoracic surgery, POAF significantly increased the mean length of hospital stay compared with patients who did not develop POAF (16.6 ± 18.6 days vs 8.2 ± 11.0 days; P < 0.001) [2] . Consequently, the mean hospital charges are higher in people with new POAF [2] . Additional charges related to outpatient treatment of POAF (e.g. beta-blockers and anticoagulation) and to complications of anticoagulation were not included in the cost assessments. Hence, the negative financial repercussions of POAF on health care systems are likely even higher than reported.
Several conditions are thought to trigger POAF after noncardiac surgery. Autonomic stimulation, electrolyte imbalances, anaemia, hypervolaemia, hypovolaemia, hypoxia and metabolic disorders are some of the proposed causes of POAF [6] . Another important proposed mechanism of POAF is inflammation [6] . The development of POAF has been associated with increased inflammatory markers such as C-reactive protein, white blood cells, interleukin-6 [7] and complements [8] [9] [10] [11] [12] [13] .
Colchicine has been used to treat inflammation in conditions such as gout and pericarditis and certain autoimmune diseases (e.g. familial Mediterranean fever) [14] . In cardiac surgery, 5 RCTs have provided evidence suggesting that colchicine prevents postpericardiotomy syndrome (PPS) and POAF [15] [16] [17] [18] [19] . In 2017, Papageorgiou et al. [20] published a meta-analysis on the effect of colchicine to prevent cardiac events after a cardiac procedure or surgery. The meta-analytic results of 4 studies, including 1118 patients and 375 events, showed that treatment with colchicine significantly reduced the risk of atrial fibrillation recurrence after cardiac surgery or pulmonary vein isolation (odds ratio 0.54, 95% CI 0.41-0.70; P = 0.001; I 2 = 1%, P = 0.39) [20] . Based on these encouraging data, we hypothesized that colchicine may prevent POAF after lung resection surgery. We carried out a multicentre pilot RCT to determine the feasibility of a large trial comparing colchicine with placebo in patients undergoing lung resection surgery. This study is entitled Colchicine for Prevention of Perioperative Atrial Fibrillation in patients undergoing lung resection surgery (COP-AF): a pilot randomized controlled study.
METHODS

Design and randomization
We conducted a multicentre pilot and feasibility parallel RCT that compared colchicine and placebo among patients having thoracic surgery. Patients, health care providers, data collectors and outcome adjudicators were blinded to treatment allocation. The appearance of the study drugs was identical. This pilot was conducted at St. Joseph Healthcare, Hamilton, Ontario and the University of Manitoba Health Sciences Centre, Winnipeg, Manitoba.
Once a patient was deemed to be eligible and written informed consent was obtained, randomization occurred a few hours before surgery. Research personnel randomized patients via an Interactive Web Randomization System (IWRS) maintained by the coordinating centre at the Population Health Research Institute (PHRI) in Hamilton, Ontario. The randomization process used block randomization stratified by centre. Study personnel and investigators were unaware of the block size. Patients were randomized in a 1:1 fashion to receive colchicine or placebo.
Institutional review board approval was obtained in both centres before the start of recruitment. A clinical trial application was also obtained from Health Canada to use colchicine for a new medical condition.
Patients and intervention
All patients > _55 years of age in sinus rhythm undergoing a tumour resection in the lung (malignant, benign or unknown) during the study period were eligible for inclusion in the trial. Patients in atrial fibrillation or atrial flutter just before surgery were excluded. Supplementary Material 1 reports the complete eligibility criteria.
On the day of surgery, patients received 0.6 mg of colchicine or placebo orally within 4 h before surgery. The second dose of colchicine 0.6 mg or placebo was given between 6:00 PM and 11:59 PM after surgery. Patients continued to receive colchicine 0.6 mg or placebo twice daily for an additional 9 days (for a total duration of treatment of 10 days). Colchicine was purchased from Pharmascience, and the Bay Area Research Laboratory undertook drug over-encapsulation (i.e. to make an identical appearing placebo), labelling, packaging and shipping.
Follow-up and data collection
All trial patients received the same structured follow-up. Study personnel followed patients throughout their hospitalization. Troponin was measured and electrocardiography (ECG) was performed once a day for the first 3 days after surgery, if patients were still in hospital [21, 22] . We systematically measured troponins after surgery because 94% of myocardial injuries after noncardiac surgery occur during the first 48 h after surgery when most patients are receiving narcotic medications that can mask ischaemic symptoms and 93% of myocardial injuries after noncardiac surgery occur without ischaemic symptoms and would go unrecognized without troponin monitoring [23, 24] . After hospital discharge, patients were either seen at their pre-planned visits in the surgical clinics or contacted via telephone, 30 days after surgery. To determine whether the participants were diagnosed with POAF after their hospital discharge, 30-day follow-up by phone or clinic visits was performed. No ECG was taken at the time of follow-up clinic visit. All postoperative ECGs in the participant's hospital chart were reviewed. All data collection was completed by the research assistants and entered through a secure Internet-based data collection system, iDataFax, under the supervision of site investigators.
Outcomes
The feasibility outcomes of this pilot study included randomizing 100 participants within a period of 18 months, completing 30-day follow-up on > _95% of patients, > _90% compliance with the study drug and determining the human and financial resources required to conduct a large trial.
The primary efficacy outcome was new-onset POAF of any duration within 30 days after randomization. Secondary efficacy outcomes and safety outcomes at 30 days after randomization included several clinical outcomes (listed and defined in Supplementary Material 2) and length of hospital stay.
Statistical analyses
We decided to recruit 100 patients. This was a convenience sample that should give us enough experience to assess our pilot objectives [25] . Analyses included all randomized patients.
We followed the intention-to-treat principle (i.e. patients were analysed within the group they were allocated).
We reported descriptive statistics for most of the feasibility outcomes (e.g. completeness of follow-up). We compared the incidence of the binary efficacy events (e.g. POAF) by allocation group using a v 2 test or the Fisher's exact test, as appropriate depending on cell size. When the cell counts are less than 5, we used the Fisher's exact test, otherwise we used the v 2 test. We compared the hospitalization and critical care length of stay durations using an independent Student's t-test or MannWhitney U-test if the assumption of normality was not satisfied. Mann-Whitney U-test was used for both outcomes. We used Cox proportional hazards models to estimate the effect of colchicine on the hazard ratio for the primary and secondary efficacy outcomes and their associated 95% CIs. Cox regression allows to determine the incidence and the time to event (POAF), important information for the design of the full-scale trial. We used alpha at 0.05 level of significance (2 sided). The statistical software SAS 9.4 was used for all analyses.
RESULTS
Recruitment, completeness of follow-up and human resources Figure 1 shows the flow of participants in the trial. Among the 205 eligible patients for COP-AF pilot, 100 patients were randomized (48.8% of eligible patients) at 2 participating centres during a 12-month period starting in April 2014. Forty-nine patients were allocated to receive colchicine and 51 to receive placebo. In the placebo group, 1 patient had his surgery cancelled. Consequently, this patient did not receive the study drug but was, however, included in the analysis based on the intention-to-treat principle. The recruitment rate was 9 participants per month. The 30-day follow-up was completed in 100% of trial participants. Study personnel took an average of 165 min per participant to complete all the tasks related to the study (e.g. recruitment and follow-up). 
Baseline characteristics
Drug compliance
Among the 99 patients who underwent surgery, 71 patients completed the study drug course without interruption (35 patients in the colchicine arm and 36 patients in the placebo group). Three additional patients completed the study drug course with interruption. There were 25 patients who did not complete the full study drug course. Overall, 77% of patients completed >85% of their study drug course (38 patients in the colchicine arm and 39 in the placebo group, P = 0.62). Table 2 reports the reasons for study drug discontinuation.
Efficacy and safety outcomes
Five patients in the colchicine arm developed new POAF and 7 patients developed POAF in the placebo group (10.2% vs 13.7%, P = 0.76). Table 3 summarizes the secondary and safety outcomes by the treatment group. Because of the in-balance in several baseline characteristics between the study groups, we undertook a post hoc Cox regression model that adjusted gender, hypertension, and coronary artery disease. This model demonstrated that perioperative colchicine intake did not significantly reduce the risk of atrial arrhythmia development (adjusted hazard ratio 0.69, 95% CI 0.20-2.34; P = 0.55) (Fig. 2 , Table 4 ). The mean time to the first occurrence of atrial fibrillation or flutter after surgery was 3.7 days and the median time was 3.4 days. One patient was unblinded. This was a 62-year-old woman who developed acute respiratory failure requiring positive pressure ventilation on postoperative Day 3. Although pneumonia was thought to be the cause of the acute respiratory distress syndrome, the patient's respirologist raised the possibility that colchicineinduced pneumonitis might be the cause. Due to the respirologist's concerns, we permanently discontinued the study drug and unblinded the patient. The patient was randomized to active colchicine. On postoperative Day 11, the patient was discharged home. A thorough review of the literature and drug monographs failed to find a case report of acute respiratory distress syndrome or pneumonitis induced by low-dose colchicine, as used in this trial; however, colchicine causing multiorgan dysfunction syndrome, including acute respiratory distress syndrome, is described in acute overdose (i.e. >0.5 mg/kg) [26, 27] . Therefore, COP-AF pilot study site investigators thought that it is unlikely that colchicine had caused pneumonitis or respiratory distress in this patient.
INTERPRETATION
We surpassed our feasibility objectives of recruitment time and completion of follow-up, and we were close to our goal of > _90% compliance with the study drug (i.e. 77% of patients took >85% of their study drugs). We were also able to determine that a single participant requires 165 min of study personnel time.
Patient baseline characteristics were comparable, except for gender, history of coronary artery disease and hypertension. Despite randomization, variability among the 2 populations was explained by the small sample size. We therefore undertook a post hoc Cox regression model that was adjusted for gender, hypertension and coronary artery disease status at baseline. Only 7% of patients recruited had active cancer. Although most thoracic surgery involves tumour resection, our low incidence of active cancers was due to our definition (i.e. active cancer: patients with a malignancy and had received chemotherapy within the last 6 months before randomization). Although our pilot study was underpowered to assess efficacy outcomes, the results were encouraging [e.g. colchicine had an adjusted hazard ratio of 0.69 (95% CI 0.20-2.34) for preventing POAF]. This point estimate of effect is plausible as other studies that investigated colchicine properties in the perioperative setting after cardiac surgery showed similar findings. Both Imazio et al.
[17] and Sarzaeem et al. [19] showed that perioperative colchicine statistically decreased the incidence of POAF (relative risk 0.55, 95% CI 0.33-0.90; relative risk 0.49, 95% CI 0.28-0.83, respectively). Caution is required in the interpretation of the results from our adjusted Cox proportional hazards models because there were few events relative to the number of included covariates. This may have resulted in an overfitted model. Clinically important bradycardia occurred more frequently in patients who received placebo (2.0% vs 17.6%, P = 0.02); however, there were only 9 patients with clinically important bradycardia in the placebo group and 1 in the colchicine group. As we have written about previously [28] , this result has great fragility and if we changed just 1 non-event patient to an event patient in the treatment group, we would reverse statistical significance. This result highlights why the results from small clinical trials are not believable, and there is a need for a large clinical trial to understand the effects of colchicine in patients undergoing lung resection surgery. The outcome of this study was POAF up to 30 days after surgery. We assumed that atrial fibrillation that occurs up to 30 days after surgery is triggered by the inflammatory process that occurs during the first 7-9 days after surgery. Therefore, suppression of this inflammatory response could still affect atrial fibrillation even beyond 9 days after surgery. However, in our study, no episodes of atrial fibrillation were diagnosed beyond the 9th day after surgery.
The potential antiplatelet properties of colchicine raised concerns about the possible risk of bleeding. According to colchicine monographs, the drug can lead to blood dyscrasias including thrombocytopenia. In our study, 1 patient experienced major bleeding in the colchicine group and 2 in the placebo arm. No patient had life-threatening bleeding. Despite small event numbers, the COP-AF pilot study did not demonstrate more bleeding events in patients randomized to colchicine. Other safety adverse events were few and similar in both groups.
To achieve adequate power to determine the effect of colchicine on the primary outcome, the full-scale trial will need to include at least 2526 participants (1263 patients per arm) to detect statistical difference. This sample size was calculated using a POAF incidence of 10%, a risk reduction of 31% (adjusted hazard ratio of 0.69 from the COP-AF pilot trial) and a power of 80%.
Limitations
We were hoping to achieve a total study drug compliance rate of 90%. However, the study drug was discontinued before the end of the intervention in 14 (28.6%) patients in the colchicine arm and in 15 (29.4%) patients in the placebo group. This drug discontinuation rate was slightly higher than the one reported in COPPS-2 trial (21.7% in the colchicine arm and 17.8% in the placebo arm) [18] . Various reasons led to permanent drug discontinuation in COP-AF pilot. Patient refusal to continue taking the study drug was the most common reason for discontinuation. Only 3 patients experienced adverse events that led to drug interruption. Overall, the study drug regimen was well tolerated by the majority of the participants.
The primary clinical outcome consisted of assessing the development of POAF. ECGs were obtained daily for the first 3 postoperative days. This method was the most feasible one but may have missed POAF at the time of doing the ECG in some patients because POAF may be transient and of short duration. Similarly, given that the mean time to the first occurrence of atrial fibrillation or flutter after surgery was 3.7 days and ECG was performed on the first 3 postoperative days only, POAF may have been missed during the subsequent days.
CONCLUSION
COP-AF pilot demonstrates the feasibility of a large trial. The results provide encouraging evidence that colchicine may safely decrease the risk of POAF in patients undergoing thoracic surgery.
